CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • August 29th, 2025 • iTeos Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of August 29, 2025 (this “Agreement”), is entered into by and between Concentra Biosciences, LLC, a Delaware limited liability company (the “Parent”), Concentra Merger Sub VIII, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the “Merger Sub”), Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company, as Rights Agent (as defined herein), and Fortis Advisors LLC, a Delaware limited liability company, solely in its capacity as the initial representative, agent and attorney in-fact of the Holders (the “Representative”).
CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • August 29th, 2025 • Concentra Biosciences, LLC • Biological products, (no disgnostic substances) • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of August 29, 2025 (this “Agreement”), is entered into by and between Concentra Biosciences, LLC, a Delaware limited liability company (the “Parent”), Concentra Merger Sub VIII, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the “Merger Sub”), Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company, as Rights Agent (as defined herein), and Fortis Advisors LLC, a Delaware limited liability company, solely in its capacity as the initial representative, agent and attorney in-fact of the Holders (the “Representative”).